TPM Vol. 32, No. S1, 2025
ISSN: 1972-6325
https://www.tpmap.org/

HYPERLIPIDEMIA: ADVANCES IN PATHOPHYSIOLOGY, RISK ASSESSMENT, AND TREATMENT STRATEGIES

HAYA FAHAD ALSUWAILEM
SARAH DHAIFALLAH ALNOFAIEI
KING ABDULAZIZ HOSPITAL, NATIONAL GUARD-AL AHSA, SAUDI ARABIA

HAURA ABDULALI DABAL
KHATOON AHMED SULIL
FATIMAH ALI ALZAHIR
BORHAN HAMAD ALSAHLI
BADER MOHAMMAD ALHARBI
PRIMARY HEALTH CARE, NATIONAL GUARD DAMMAM, DAMMAM, SAUDI ARABIA

SULTAN YAHYA ZAYLAEE
IMAM ABDULRAHMAN BIN FAISAL HOSPITAL, NATIONAL GUARD DAMMAM, SAUDI ARABIA

Abstract:
Background: Hyperlipidemia is a critical health condition characterized by elevated lipid levels in the blood, necessitating comprehensive management strategies to mitigate cardiovascular risks and improve long-term health outcomes
Aim: Understanding of the pathophysiology of hyperlipidemia, to evaluate current and emerging tools for risk assessment, and to explore novel and established treatment strategies for improving lipid management and reducing cardiovascular risk.
Method: The PubMed and Google Scholar Search Engines were the primary databases used for the search process, with articles collected from 1970 to 2025.
Conclusion: Hyperlipidemia is a major health issue linked to cardiovascular disease, highlighting the need for proper diagnosis and management to lower risks and avoid severe complications. Key contributors to hyperlipidemia include obesity, diabetes, hypertension, smoking, inactivity, family history, genetics, age, gender, and chronic stress. An effective treatment plan for hyperlipidemia should encompass the use of statins or lipid-lowering drugs, dietary modifications, regular exercise, weight management, and smoking cessation to reduce cardiovascular risk and improve lipid levels.

Keywords: Hyperlipidemia, Pathophysiology, Cardiovascular Risk Factors and Treatment strategies.

INTRODUCTION

Hyperlipidemia is defined as an elevation of one or more types of lipids in the bloodstream, including cholesterol and triglycerides, which significantly increases the risk of cardiovascular diseases such as coronary artery disease, heart attacks, and strokes. The condition is typically diagnosed through a lipid profile, a blood test that measures levels of total cholesterol, LDL (low-density lipoprotein, or "bad") cholesterol, HDL (high-density lipoprotein, or "good") cholesterol, and triglycerides. High levels of LDL cholesterol and triglycerides are particularly concerning, as they contribute to the development of hyperlipidemia and associated cardiovascular risks. [1]



FIGURE (1): TYPE OF HYPERLIPIDEMIA

TYPE OF HYPERLIPIDEMIA

Hyperlipidemia is classified into several types based on its underlying causes and characteristics. The Fredrickson Classification System is a crucial framework for categorizing hyperlipidemia into six distinct types based on lipoprotein profiles, which aids in diagnosis and treatment planning [Table1]. But the two main primary categories are primary and secondary hyperlipidemia. **Primary Hyperlipidemia** is primarily due to genetic factors, leading to elevated lipid levels in the blood, which significantly increases the risk of cardiovascular diseases. In contrast, **Secondary Hyperlipidemia** arises from non-genetic factors such as diet, obesity, and certain medications, and can often be managed through lifestyle changes and medical treatment. Within these categories, specific conditions can be identified. **Familial hypercholesterolemia** is a notable genetic disorder characterized by very high levels of LDL cholesterol, which poses a significant risk for premature cardiovascular disease. **Combined hyperlipidemia**, on the other hand, involves elevated levels of both cholesterol and triglycerides, often necessitating a multifaceted management approach that includes dietary changes and medication. **Isolated Hypercholesterolemia** refers to high cholesterol levels without significant elevation of triglycerides, which can be managed through lifestyle changes and medications. **Hypertriglyceridemia** specifically refers to high triglyceride levels in the blood, which can lead to pancreatitis and cardiovascular issues, often linked to obesity and a high-fat diet. Additionally, **Acquired Hyperlipidemia** results from lifestyle factors and medical conditions, while elevated lipid levels characterize **Idiopathic Hyperlipidemia** without a known cause. Moreover, certain diseases, such as hypothyroidism and Cushing's syndrome, can also lead to hyperlipidemia, emphasizing the importance of managing underlying conditions. Rare genetic disorders, such as lipoprotein lipase deficiency and ApoA-I deficiency, further illustrate the complexity of hyperlipidemia, which affects triglyceride and HDL cholesterol levels, respectively. Understanding these various types is crucial for effective diagnosis and treatment.[2-6]

TABLE (1): FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIA [7]

Type	Familiar name	Lipoprotein abnormality	Underlying defect
1	Exogenous dietary hypertriglyceride	Elevated chylomicrons and TG	Mutation in lipoprotein lipase gene.
2a	Familial hypercholesterolemia	Elevated LDL-cholesterol	A mutation in the LDL receptor gene or the apolipoprotein B gene.
2b	Combined hyperlipidemia	Elevated LDL, VLDL, and TG	A mutation in the LDL receptor gene or the apolipoprotein B gene.
3	Remnant hyperlipidemia	Increased remnants (chylomicrons), VLDL, and cholesterol.	A mutation in the apolipoprotein E gene.

4	Endogenous hyperlipidemia	Elevated VLDL and TG.	Unknown.
5	Mixed hypertriglyceridemia	Elevated VLDL, chylomicrons, and TG	A mutation in the apolipoprotein C11 gene.
(Chylomicrons) Triglyceride rich carrier of dietary fats, (VLDL) Very Low Density Lipoprotein – Triglyceride rich carrier of hepatic synthesized triglycerides (TG), (IDL & LDL) Intermediate and Low Density Lipoprotein - Cholesterol rich remnant particles derived from lipolysis of triglycerides in VLDL, (HDL) High Density Lipoprotein - Cholesterol rich particle that transports cholesterol to liver for disposal or recycling			

PATHOPHYSIOLOGY OF HYPERLIPIDEMIA

Hyperlipidemia encompasses a range of genetic disorders characterized by elevated lipid levels in the blood, which can lead to significant cardiovascular complications. The pathophysiology of these conditions is complex, involving various genetic mutations that affect lipid metabolism. One of the most common forms of hyperlipidemia is familial hypercholesterolemia, which is primarily caused by mutations in the LDL receptor gene. This defect impairs the liver's ability to clear low-density lipoprotein (LDL) from the bloodstream, leading to elevated cholesterol levels and an increased risk of atherosclerosis and cardiovascular disease. Another related condition is familial defective apolipoprotein B-100, which results from mutations in the apoB gene. This mutation leads to a failure of LDL binding to its receptor, resulting in the further accumulation of LDL in the plasma. Additionally, autosomal dominant hypercholesterolemia is another hereditary condition that results from mutations affecting LDL metabolism, inherited in an autosomal dominant pattern.

This condition also contributes to elevated cholesterol levels and associated cardiovascular risks. Conversely, autosomal recessive hypercholesterolemia, caused by different mutations affecting cholesterol metabolism, leads to even more severe elevations in cholesterol levels. Lysosomal acid lipase deficiency is another genetic disorder that results in lipid accumulation due to a deficiency in the enzyme responsible for breaking down lipids, further complicating the lipid profile in affected individuals. [2] Similarly, LP-lipase deficiency, caused by mutations in the LP-lipase or apo C-II genes, leads to defective metabolism of chylomicrons and VLDL, resulting in extreme hypertriglyceridemia and associated symptoms such as eruptive xanthomas and pancreatitis. Type III hyperlipemia, characterized by the accumulation of chylomicron and VLDL remnants, is another disorder that requires additional genetic, hormonal, or environmental factors for its manifestation. Mutations in apoE are implicated in this condition, leading to further complications in lipid metabolism. [8]

The pathophysiology of hyperlipidemia is multifaceted, involving various physiological and pathological mechanisms that lead to alterations in lipid metabolism. One significant contributor to hyperlipidemia is abnormal glomerular permeability to plasma proteins, which is particularly relevant in conditions like nephrotic syndrome. This abnormality can lead to nephrotic syndrome, characterized by hyperlipidemia, where the loss of proteins in urine results in reduced serum oncotic pressure, further exacerbating lipid abnormalities. In nephrotic syndrome, the etiology of hyperlipidemia is not fully understood, but it is believed that both the aforementioned glomerular permeability issues and reduced oncotic pressure play critical roles. These changes can lead to increased synthesis and decreased catabolism of lipids and lipoproteins, resulting in elevated lipid levels in the bloodstream. Additionally, hyperlipidemia can induce renal injury through inflammatory and immunologically mediated mechanisms, which can further complicate the condition. [9]

Other underlying disorders, such as diabetes mellitus, hypothyroidism, and renal failure, also contribute to acquired hyperlipidemia by altering lipid metabolism. For instance, diabetes mellitus is known to disrupt normal lipid processing, leading to secondary dyslipoproteinemia. Similarly, hypothyroidism and renal failure can cause significant changes in lipid profiles, contributing to the overall hyperlipidemic state. Moreover, lifestyle factors such as alcohol usage can exacerbate hyperlipidemia by affecting lipid metabolism, further complicating the clinical picture. [10] The presence of hypertriglyceridemia is particularly notable in patients treated with certain medications, such as azathioprine and prednisone, where increased caloric intake and glucose intolerance due to steroids can lead to elevated triglyceride levels. [11] Moreover, Hyperlipidemia is intricately linked to obesity, which serves as a significant risk factor for its development. The pathophysiology of hyperlipidemia in obese individuals involves a complex interplay of metabolic dysfunctions, particularly related to adipose tissue, insulin resistance, and lipoprotein metabolism. Obesity leads to an increase in adipose tissue, which is not merely a passive energy store but an active endocrine organ that influences lipid metabolism. Dysfunctional adipose tissue can contribute to insulin resistance, a condition in which cells fail to respond effectively to insulin, thereby exacerbating hyperlipidemia by promoting increased hepatic production of triglycerides and reducing the clearance of lipoproteins from the bloodstream.[12,13]

This insulin resistance is often associated with an increase in free fatty acids released from adipose tissue, further amplifying lipid dysregulation and promoting atherogenic processes.[14]

RISK FACTORS FOR HYPERLIPIDEMIA

Obesity is a primary contributor, as excess body fat can lead to increased levels of LDL cholesterol, thereby heightening cardiovascular risk. Similarly, diabetes is a critical risk factor; high blood sugar levels can elevate LDL cholesterol and triglycerides, necessitating careful management to prevent cardiovascular complications. Hypertension also plays a vital role, as high blood pressure can exacerbate lipid abnormalities, increasing the risk of cardiovascular events. Smoking is another major risk factor, damaging the cardiovascular system and raising LDL cholesterol levels, making smoking cessation essential for hyperlipidemia management. Physical inactivity significantly contributes to hyperlipidemia, as a sedentary lifestyle is associated with lower levels of HDL cholesterol and higher levels of LDL cholesterol. Regular exercise is crucial for mitigating these risks.
Additionally, a family history of hyperlipidemia indicates a genetic predisposition, underscoring the importance of genetic screening and early intervention. Age is another critical factor, with the risk of hyperlipidemia increasing as individuals grow older, necessitating regular health check-ups. Gender differences also exist, as men are generally at higher risk, although post-menopausal women face increased susceptibility. Chronic stress can further complicate lipid profiles by raising cortisol levels, which in turn can elevate LDL cholesterol and triglycerides. Lastly, certain medications, including beta-blockers and diuretics, can also contribute to hyperlipidemia, highlighting the need for regular monitoring of medication effects. [2,10,15-19]

CLINICAL MANIFESTATION OF HYPERLIPIDEMIA

Hyperlipidemia is usually Asymptomatic, but several clinical signs can serve as important indicators of underlying lipid disorders and increased cardiovascular risk [Figure 2]. One of the most recognizable manifestations is xanthelasma, which presents as yellowish patches around the eyes and is often linked to elevated cholesterol levels. This condition not only signifies lipid accumulation but also raises concerns regarding cardiovascular disease risk. Another notable manifestation is corneal arcus, characterized by a white, grey, or blue opaque ring at the corneal margin. This condition is particularly prevalent in older adults and can indicate high cholesterol levels, serving as a potential marker for coronary artery disease. Similarly, tuberous xanthomas, which appear as firm nodules on areas such as the elbows and knees, and eruptive xanthomas, presenting as small yellowish bumps on the buttocks and thighs, are both associated with hyperlipidemia and signal an increased cardiovascular risk. Palmar xanthomas, which manifest as yellowish patches on the palms, further illustrate the diverse range of skin lesions associated with lipid disorders. Additionally, hypertriglyceridemia, characterized by elevated triglyceride levels, is a common clinical manifestation of hyperlipidemia that can lead to serious complications such as pancreatitis and cardiovascular disease. Atherosclerosis, the buildup of plaque in the arteries, is another critical consequence of hyperlipidemia, significantly increasing the risk of heart attacks and strokes. [20]



FIGURE (2): (A) CORNEAL ARCUS AND XANTHELASMA; (B) EXTENSOR TENDON XANTHOMAS; (C AND D) ACHILLES TENDON XANTHOMAS.

TREATMENT STRATEGIES

Treating hyperlipidemia effectively requires a multifaceted approach that combines pharmacological interventions and lifestyle modifications. Statins, such as rosuvastatin and atorvastatin, are often the first line of treatment due to their efficacy in lowering LDL cholesterol levels and reducing cardiovascular risk. In cases where triglyceride levels are also elevated, fibrates can be used, particularly in combination with statins for optimal lipid management. Bile acid sequestrants may also be prescribed in conjunction with statins to further lower LDL cholesterol by preventing the reabsorption of bile acids. In addition to medication, lifestyle changes play a crucial role in managing hyperlipidemia. A diet rich in soluble fiber, such as that found in oats and fruits, can help lower LDL cholesterol levels. Regular exercise is beneficial as it can raise HDL cholesterol levels and lower triglyceride levels, contributing to overall cardiovascular health. Furthermore, maintaining a healthy weight is essential, as excess weight can exacerbate lipid levels and increase cardiovascular risk. Smoking cessation is another critical component, as smoking is a well-known risk factor for cardiovascular disease. Supplementing with omega-3 fatty acids, found in fatty fish and flaxseeds, can also help lower triglyceride levels and improve lipid profiles. Niacin may be considered as an adjunct therapy to raise HDL cholesterol, although it should be used with caution due to potential side effects. [19,21]

CONCLUSION

Hyperlipidemia is a major health issue linked to cardiovascular disease, highlighting the need for proper diagnosis and management to lower risks and avoid severe complications. Key contributors to hyperlipidemia include obesity, diabetes, hypertension, smoking, inactivity, family history, genetics, age, gender, and chronic stress. An effective treatment plan for hyperlipidemia should encompass the use of statins or lipid-lowering drugs, dietary modifications, regular exercise, weight management, and smoking cessation to reduce cardiovascular risk and improve lipid levels.

CONFLICT OF INTEREST

Authors declare they don’t have any conflict of interest.

ACKNOWLEDGEMENT

The authors would like to thank the publicly available online library resources for helping them to perform a comprehensive literature review. Finally, the corresponding author's insightful comments significantly raised the caliber of the manuscript, for which the authors are truly grateful.

AUTHOR CONTRIBUTIONS

Even though each author contributed significantly through data collection and literature searches, the initial author wrote the original text. Each author accepted full responsibility for the work, took part in the critical revision of the paper, and gave their approval to the final draft.

ETHICAL APPROVAL

Not Applicable

REFERENCES

1. Rizvi NB, Nagra SA, Rizvi NB, Nagra SA: Discussion: Lipid Profile. Minerals and Lipids Profiles in Cardiovascular Disorders in South Asia: Cu, Mg, Se, Zn and Lipid Serum Profiles for the Example of Patients in Pakistan. 2014:123-140.
2. Holmes DT: Primary Hyperlipidemias: An Atlas of Investigation and Diagnosis. The Canadian Journal of Cardiology. 2008, 24:406.
3. Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M: A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Panminerva medica. 2012, 54:91.

4. Miller M: Current perspectives on the management of hypertriglyceridemia. American heart journal. 2000, 140:232-240.
5. Ross CJ, Twisk J, Kuivenhoven JA, et al.: 40. Correction of Dyslipidemia in Murine and Feline Models of Lipoprotein Lipase Deficiency by Intramuscular Administration of AAV1-LPLS447X. Molecular Therapy. 2004, 9:S17.
6. Rajmohan L, Deepa R, Mohan A, Mohan V: Association between isolated hypercholesterolemia, isolated hypertriglyceridemia and coronary artery disease in south Indian type 2 diabetic patients. Indian heart journal. 2000, 52:400-406.
7. Fredrickson DS: An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971, 75:471-472. 10.7326/0003-4819-75-3-471
8. Sandhofer F: Physiology and pathophysiology of the metabolism of lipoproteins. Wiener Medizinische Wochenschrift (1946). 1994, 144:286-290.
9. Hutchison F: Proteinuria, hyperlipidemia, and the kidney. Mineral and electrolyte metabolism. 1993, 19:127-136.
10. Chait A, Brunzell JD: Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinology and metabolism clinics of North America. 1990, 19:259-278.
11. Zi D: Dietotherapy for hyperlipidemia. Journal of Traditional Chinese Medicine. 2009, 29:286-287.
12. Colaianni G, Colucci S, Grano M: Anatomy and physiology of adipose tissue. Multidisciplinary Approach to Obesity: From Assessment to Treatment. 2015:3-12.
13. Ofei F: Obesity-a preventable disease. Ghana medical journal. 2005, 39:98.
14. Olefsky JM, Kolterman OG: Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. The American journal of medicine. 1981, 70:151-168.
15. Borghi C: Interactions between hypercholesterolemia and hypertension: implications for therapy. Current opinion in nephrology and hypertension. 2002, 11:489-496.
16. Handa K, Tanaka H, Shindo M, Kono S, Sasaki J, Arakawa K: Relationship of cigarette smoking to blood pressure and serum lipids. Atherosclerosis. 1990, 84:189-193.
17. Hanefeld M, Leonhardt W, Fischer S, et al.: Therapeutical effects of endurance training in primary hyperlipoproteinemia. In Atherosclerosis VI: Proceedings of the Sixth International Symposium. Springer; 1983:262-267.
18. Nelson RH: Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013, 40:195-211. 10.1016/j.pop.2012.11.003
19. Feingold KR: Guidelines for the management of high blood cholesterol. Endotext [Internet]. 2025.
20. Bell D, Hooper A, Watts G, Burnett J: Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vascular health and risk management. 2012, 8:651-659. 10.2147/VHRM.S28581
21. Last AR, Ference JD, Falleroni J: Pharmacologic treatment of hyperlipidemia. American family physician. 2011, 84:551-558.